Dr Lal Pathlabs Ltd News
Dr Lal PathLabs Q3 net profit falls 6.4% on new labour code impact
Diagnostics major reports a one-time charge linked to new labour codes even as revenue rose over 10% on higher sample volumes and network expansion
 "Dr Lal PathLabs Q3 net profit falls 6.4% on new labour code impact")
Dr Lal Path Labs Q3 results: PAT dips to ₹90.5 cr on labour code changes
The country's largest diagnostics firm by revenue took up a one-time charge worth ₹30.1 crore linked to India's new labour codes
HDFC Sec turns bullish on Dr Lal PathLabs; upgrades to 'Buy'; raises target
Dr Lal PathLabs is focusing on innovation, including new wellness packages and high-end, super-speciality tests, with a focus on capturing prescription shares
 "HDFC Sec turns bullish on Dr Lal PathLabs; upgrades to 'Buy'; raises target")
Stocks gaining momentum? Here's why Escorts, Hudco, 3 others are on radar
Technical charts show Escorts, Hudco, Dr Lal PathLabs, Force Motors and Godrej Consumer were trading above the higher-end of the Bollinger Bands on the daily scale; and can potentially rally up to 23%
 "Stocks gaining momentum? Here's why Escorts, Hudco, 3 others are on radar")
Dr Lal PathLabs Q2 results: PAT up 16.4% at ₹152 crore, revenue rises 11%
Diagnostics chain declares ₹7 per share interim dividend, 1:1 bonus issue
 "Dr Lal PathLabs Q2 results: PAT up 16.4% at ₹152 crore, revenue rises 11%")
Will Apollo, Max, Metropolis outshine peers in Q2? Here's what analysts say
Domestic brokerage firm Nuvama analysts forecast a modest sequential slowdown but a healthy ~17 per cent year-on-year (Y-o-Y) Ebitda growth, led by hospitals and diagnostics.
 "Will Apollo, Max, Metropolis outshine peers in Q2? Here's what analysts say")